Advertisement

Legal Implications of Adverse Drug Reactions

  • Edward C. RosenowIII
  • Scott E. Rosenow

Abstract

Americans are a drug-taking society. They take 2 to 10 times more prescription and over-the-counter drugs than a comparable population anywhere else in the world. The hospitalized patient takes an average of 6 to 13 drugs. The risk-benefit ratio of this many medications is unknown. However, there is no question that medications have saved and prolonged many lives. As there is no mandatory reporting of adverse drug reactions (ADR) in this county, we have no way of knowing what percent of drugs taken produces adverse side effects.1 More than 1.6 billion prescriptions for more than 30,000 different drugs are written each year in the United States,1 with about 200 new drugs approved each year. The estimates of significant side effects, meaning adverse drug reactions, range from tens of thousands to several million per year!

Keywords

Adverse Drug Reaction Package Insert Adverse Drug Reaction Report Legal Implication Boston Collaborative Drug Surveillance Program 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Edlavitch SA: Adverse drug event reporting. Improving the low US reporting rates. Arch Int Med 1988;148: 1499–1503.CrossRefGoogle Scholar
  2. 2.
    Caranasos GJ, Stewart RB, CLiff LE: Drug-induced illness leading to hospitalization. J Am Med Assoc 1974;228:713–717.CrossRefGoogle Scholar
  3. 3.
    Miller RR: Hospital admissions due to adverse drug reactions. A report from the Boston Collaborative Drug Surveillance program. Arch Intern Med 1974;134:219–223.CrossRefGoogle Scholar
  4. 4.
    Shapiro S, Slone D, Lewis GP, et al: Fatal drug reactions among medical inpatients. J Am Med Assoc 1971;216:467–472.CrossRefGoogle Scholar
  5. 5.
    Friedman GD, Collen MF, Harris LE, et al: Experience in monitoring drug reactions in outpatients. The Kaiser-Permanente drug monitoring system. J Am Med Assoc 1971;217:567–572.CrossRefGoogle Scholar
  6. 6.
    Porter J, Jick H: Drug-related deaths among medical inpatients. J Am Med Assoc 1977;237:879–881.CrossRefGoogle Scholar
  7. 7.
    Talley RB, Laventurier MF: Drug-induced illness (letter to the editor). J Am Med Assoc 1974;229:1043.CrossRefGoogle Scholar
  8. 8.
    Stetler CJ: Drug-induced illness (letter to the editor). J Am Med Assoc 1974;229:1043–1044.CrossRefGoogle Scholar
  9. 9.
    Ballin JC: The ADR numbers game. J Am Med Assoc 1974;229:1097–1098.CrossRefGoogle Scholar
  10. 10.
    Koch-Weser J: Fatal reactions to drug therapy. N Engl J Med 1974;291:302–303.CrossRefGoogle Scholar
  11. 11.
    Karch FF, Lasagna L: Adverse drug reactions. A critical review. J Am Med Assoc 1975;234:1236–1241.CrossRefGoogle Scholar
  12. 12.
    Modern Medicine 16:K-L, April 1974.Google Scholar
  13. 13.
    DeSwarte RD, Patterson R: Adverse drug reactions. The clinician’s role in reporting. Arch Intern Med 1986;146:649–650.CrossRefGoogle Scholar
  14. 14.
    Holmberg L, Boman G, Bottiger LE, et al: Adverse reactions to introfurantoin. Analysis of 921 reports. Am J Med 1980;69:733–738.CrossRefGoogle Scholar
  15. 15.
    Holmberg L, Boman G: Pulmonary reactions to nitrofurantoin: 447 cases reported to the Swedish Adverse Drug Reaction Committee. 1966–1976. Eur J Respir Dis 1981;62:180–189.Google Scholar
  16. 16.
    D’Arcy PF: Drug interactions and reactions update. Nitrofurantoin. Drug Int ell Clin Pharm 1985;19:540–547.Google Scholar
  17. 17.
    Koch-Weser J, Sidel VW, Dexter M, et al: Adverse reactions to sulfisoxazole, sulfamethoxazole, and nitrofurantoin. Arch Intern Med 1971;128:399–404.CrossRefGoogle Scholar
  18. 18.
    Cooper JA Jr, White DA, Matthay RA: Drug-induced pulmonary disease: Part I: Cytotoxic drugs. Am Rev Respir Dis 1986;133:321–340.Google Scholar
  19. 19.
    Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary disease: Part II: Noncytotoxic drugs. Am Rev Respir Dis 1986;133:488–505.Google Scholar
  20. 20.
    Gilhooley M: Learned intermediaries, prescription drugs and patient information. St Louis Univ Law J 1986;30:633.Google Scholar
  21. 21.
    Therapeutic misadventures: Drugs, in CG Tedeschi, WC Eckert, LG Tedeschi (eds): Forensic Medicine, Vol III. Philadelphia, WB Saunders Co, 1977, pp 1195–1225.Google Scholar
  22. 22.
    Agnew v. Larson, 185 P.2d 851 (Cal. 1947).Google Scholar
  23. 23.
    Rotan v. Greenbaum, 273 F.2d 830 (Dist. Ct. Cal. 1959).Google Scholar
  24. 24.
    Gooden v. Tips, 651 S.W. 2d 364 (Ca. Tex. 1983).Google Scholar
  25. 25.
    Yorston v. Pennell, 253 A. 2d 255 (Pa. 1959).Google Scholar
  26. 26.
    Stokes v. Dailey, 85 N.W. 2d 745 (N.D. 1957).Google Scholar
  27. 27.
    Whitfield v. Daniel Construction Co., S.E. 2d 460 (S.C. 1954).Google Scholar
  28. 28.
    Kaiser v. Suburban Transportation System, 398 P. 2d 14 (Wash. 1965).Google Scholar
  29. 29.
    Marsh v. Arnold, 446 S.W. 2d 949 (Tex. 1969).Google Scholar
  30. 30.
    Sharpe v. Pugh, 155 S.E. 2d 108 (N.C. 1967).Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • Edward C. RosenowIII
  • Scott E. Rosenow

There are no affiliations available

Personalised recommendations